DrugPatentWatch Database Preview
Abbvie Inc Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for ABBVIE INC, and what generic alternatives to ABBVIE INC drugs are available?
ABBVIE INC has ten approved drugs.
There are forty-nine US patents protecting ABBVIE INC drugs.
There are nine hundred and sixty-seven patent family members on ABBVIE INC drugs in fifty-three countries and ninety supplementary protection certificates in eighteen countries.
Summary for Abbvie Inc
| International Patents: | 967 |
| US Patents: | 49 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 10 |
| Drug Master File Entries: | 15 |
| Patent Litigation for Abbvie Inc: | See patent lawsuits for Abbvie Inc |
Drugs and US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | RX | Yes | No | 7,462,625 | Start Trial | Y | Y | Start Trial | ||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | 9,044,480 | Start Trial | Start Trial | ||||
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | RX | Yes | No | 6,872,728 | Start Trial | Y | Y | Start Trial | ||
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | Start Trial | Start Trial | |||||
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | RX | Yes | Yes | 9,629,841 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | 6,037,157*PED | Start Trial |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-003 | Sep 4, 2001 | 6,652,881 | Start Trial |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,652,881 | Start Trial |
| Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | 7,148,359 | Start Trial |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,277,405 | Start Trial |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-003 | Sep 4, 2001 | 6,277,405 | Start Trial |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-003 | Sep 4, 2001 | 6,074,670 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
International Patents for Abbvie Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| San Marino | T201500263 | Start Trial |
| South Korea | 20180099929 | Start Trial |
| Slovenia | 2576546 | Start Trial |
| South Korea | 101481395 | Start Trial |
| Switzerland | 707030 | Start Trial |
| Mexico | 346264 | Start Trial |
| New Zealand | 591973 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Abbvie Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435432 | PA2017015,C2435432 | Lithuania | Start Trial | PRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205 |
| 2340029 | 304 50009-2015 | Slovakia | Start Trial | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119 |
| 2618831 | 2017C/041 | Belgium | Start Trial | PRODUCT NAME: GLECAPREVIR OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728 |
| 2368890 | 2015/010 | Ireland | Start Trial | PRODUCT NAME: OMBITASVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| 2435432 | 2017/023 | Ireland | Start Trial | PRODUCT NAME: VENETOCLAX (VENCLYXTO); REGISTRATION NO/DATE: EU/1/16/1138 20161205 |
| 2340029 | CA 2015 00013 | Denmark | Start Trial | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150115 |
| 2618831 | C201730038 | Spain | Start Trial | PRODUCT NAME: GLECAPREVIR O UNA SAL O ESTER FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1213; DATE OF AUTHORISATION: 20170726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1213; DATE OF FIRST AUTHORISATION IN EEA: 20170726 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
